Detailed Information

Cited 40 time in webofscience Cited 41 time in scopus
Metadata Downloads

Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-upopen access

Authors
Lee, Jeong-HoonLee, Joon HyeokLim, Young-SukYeon, Jong EunSong, Tae-JinYu, Su JongGwak, Geum-YounKim, Kang MoKim, Yoon JunLee, Jae WonYoon, Jung-Hwan
Issue Date
Jan-2019
Publisher
Springer Verlag
Keywords
Hepatocellular carcinoma; Cytokine-induced killer cell; Adjuvant immunotherapy; Recurrence-free survival; Overall survival
Citation
Cancer Immunology, Immunotherapy, v.68, no.1, pp.23 - 32
Indexed
SCIE
SCOPUS
Journal Title
Cancer Immunology, Immunotherapy
Volume
68
Number
1
Start Page
23
End Page
32
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/2525
DOI
10.1007/s00262-018-2247-4
ISSN
0340-7004
Abstract
Our earlier multicenter randomized controlled trial showed that adjuvant immunotherapy with cytokine-induced killer (CIK) cells resulted in longer recurrence-free survival (RFS) and overall survival (OS) as well in patients who received curative treatment for hepatocellular carcinoma (HCC). In the present study, we determined if the efficacy of CIK cell therapy continued after end of repeated CIK cell injections. We performed a follow-up study of our preceding trial. We included 226 patients: 114 patients in the immunotherapy group (injection of 6.4x10(9) CIK cells, 16 times during 60 weeks) and 112 patients in the control group (no treatment) after potentially curative treatment for HCC. In total, 162 patients (89 of the immunotherapy group and 73 of controls) underwent an extended follow-up for 60months after randomization of the last patient. The primary endpoint was RFS, and secondary endpoints included OS. During follow-up time of median 68.5months (interquartile range 45.0-82.2months), the immunotherapy group continued to show a significantly lower risk of recurrence or death [hazard ratio (HR) 0.67; 95% confidence interval (CI) 0.48-0.94; P=0.009 by one-sided log-rank test]. At 5 years, RFS rate was 44.8% in the immunotherapy group and 33.1% in the control group. The risk of all-cause death was also lower in the immunotherapy group compared to the control group (HR 0.33; 95% CI 0.15-0.76; P=0.006). In patients who received curative treatment for HCC, the significant improvement in RFS and OS as a result of adjuvant CIK cell immunotherapy lasted over 5years without boosting.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Hepato-Biliary-Pancreatic Surgery > 1. Journal Articles
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Yeon, Jong Eun photo

Yeon, Jong Eun
Guro Hospital (Department of Gastroenterology and Hepatology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE